Additionally, the 36-month beta value for DRMA is 0.60. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for DRMA is 4.43M and currently, short sellers hold a 2.73% ratio of that float. The average trading volume of DRMA on May 01, 2025 was 1.50M shares.
DRMA) stock’s latest price update
The stock price of Dermata Therapeutics Inc (NASDAQ: DRMA) has jumped by 11.27 compared to previous close of 0.75. Despite this, the company has seen a gain of 5.78% in its stock price over the last five trading days. accessnewswire.com reported 2025-04-15 that – Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial – – Additional data analysis revealed that XYNGARI(TM) separated from placebo after just four once-weekly treatments – – XYNGARI(TM) could be the first once-weekly topical product candidate for moderate-to-severe acne – SAN DIEGO, CA / ACCESS Newswire / April 15, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) (“Dermata” or the “Company”), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced that additional analysis of topline data from its Phase 3 STAR-1 trial showed that XYNGARI™ had a statistically significant difference from placebo on three efficacy endpoints as early as week 4, which occurred after just four treatments with XYNGARI™. XYNGARI™ Phase 3 STAR-1 Topline Week 4 Efficacy Results In the intent to treat analysis, Dermata saw statistically significant differences in IGA treatment success, inflammatory lesion count, and non-inflammatory lesion count at week 4 (earliest measured timepoint) when compared to placebo.
DRMA’s Market Performance
DRMA’s stock has risen by 5.78% in the past week, with a monthly drop of -22.39% and a quarterly drop of -30.73%. The volatility ratio for the week is 12.94% while the volatility levels for the last 30 days are 11.73% for Dermata Therapeutics Inc The simple moving average for the past 20 days is 4.26% for DRMA’s stock, with a -40.10% simple moving average for the past 200 days.
DRMA Trading at -19.55% from the 50-Day Moving Average
After a stumble in the market that brought DRMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.42% of loss for the given period.
Volatility was left at 11.73%, however, over the last 30 days, the volatility rate increased by 12.94%, as shares sank -16.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.99% lower at present.
During the last 5 trading sessions, DRMA rose by +5.78%, which changed the moving average for the period of 200-days by -63.24% in comparison to the 20-day moving average, which settled at $0.8040. In addition, Dermata Therapeutics Inc saw -37.91% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for DRMA
The total capital return value is set at -8.02. Equity return is now at value -310.44, with -213.46 for asset returns.
Currently, EBITDA for the company is -12.51 billion with net debt to EBITDA at 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.79.
Conclusion
In conclusion, Dermata Therapeutics Inc (DRMA) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
